Baird Financial Group Inc. Sells 98,410 Shares of Merck & Co., Inc. $MRK

Key Points

• Baird Financial Group reduced its Merck stake by 8.5%, selling 98,410 shares and retaining 1.06 million shares valued at approximately $136.8 million. Institutional investors collectively own 76.07% of MRK.
• Wall Street sentiment remains favorable, with 15 analysts rating Merck a Buy and eight a Hold. The stock has a “Moderate Buy” consensus rating and an average price target of $149.80, while several firms recently raised their targets as high as $175.
• Merck’s growth outlook continues to rely heavily on Keytruda, with investors monitoring its ability to offset the drug’s expected 2028 patent expiration. Elevated valuation and past Gardasil sales weakness remain key risks, despite recent revenue growth and a quarterly dividend of $0.85 per share.

Baird Financial Group Inc. lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 8.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,064,683 shares of the company's stock after selling 98,410 shares during the period. Baird Financial Group Inc.'s holdings in Merck & Co., Inc. were worth $136,812,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Round Rock Advisors LLC lifted its position in Merck & Co., Inc. by 0.7% during the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company's stock worth $1,272,000 after buying an additional 66 shares in the last quarter. Cascade Financial Partners LLC increased its position in Merck & Co., Inc. by 0.5% in the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock valued at $1,895,000 after acquiring an additional 80 shares in the last quarter. Somerset Trust Co raised its stake in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company's stock worth $1,118,000 after acquiring an additional 81 shares during the last quarter. Stonebridge Financial Group LLC raised its stake in shares of Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock worth $1,124,000 after acquiring an additional 81 shares during the last quarter. Finally, Stronghold Wealth Management L.L.C. increased its holdings in shares of Merck & Co., Inc. by 2.6% in the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock valued at $416,000 after purchasing an additional 82 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Guggenheim raised its price target to $170 from $146 and reiterated a “Buy” rating, implying roughly 14.5% upside from the referenced price. The upgrade provides a bullish signal and may support MRK by indicating confidence in Merck’s earnings outlook and product pipeline. Benzinga analyst note
• Positive Sentiment: Keytruda continues to drive Merck’s growth, while newer products and pipeline programs could help offset the expected impact of the drug’s 2028 patent cliff. The company’s strong recent return and revenue momentum reinforce the longer-term growth case. Merck trading near 52-week high analysis
• Neutral Sentiment: Merck will participate in Morgan Stanley’s 24th Annual Global Healthcare Conference. The event could provide updates on Keytruda, Gardasil, pipeline assets, and post-2028 planning, but no new financial information was disclosed in the announcement. Morgan Stanley healthcare conference announcement
• Neutral Sentiment: Merck is participating in a cocoa traceability and digital product-passport pilot with The Hashgraph Group and PwC Germany. The initiative may support corporate sustainability efforts but is unlikely to materially affect near-term earnings. Cocoa traceability partnership
• Negative Sentiment: MRK’s valuation is elevated after its substantial rally, increasing the risk that investors will demand continued strong execution. Analysts and investors are also watching whether Merck can replace Keytruda revenue after the 2028 patent expiration. Merck Gardasil and future growth analysis
• Negative Sentiment: Gardasil’s earlier sales decline remains part of the investment debate, even though management is now emphasizing longer-term growth opportunities. Continued vaccine-market pressure could weigh on sentiment until the company demonstrates a sustained recovery. Gardasil outlook analysis

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares of the company's stock, valued at $6,106,303. This represents a 24.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock worth $29,977,783 in the last three months. 0.17% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Scotiabank upped their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a report on Tuesday, June 30th. Daiwa Securities Group raised Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price objective for the company in a report on Wednesday, August 12th. BMO Capital Markets upped their target price on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the company an "outperform" rating in a research report on Thursday, August 20th. UBS Group raised their target price on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 20th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and a consensus price target of $149.80.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $148.44 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $156.92. The firm has a fifty day moving average of $135.46 and a 200-day moving average of $123.92. The firm has a market capitalization of $366.23 billion, a price-to-earnings ratio of 118.75, a price-to-earnings-growth ratio of 6.54 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the business posted $2.13 EPS. The firm's revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck's pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.